Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: Use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol

Transplantation

Volumn 67, Issue 9, 1999, Pages 1209-1214

  Birkeland, Sven Arvid ^a   Andersen, H K ^b   Hamilton Dutoit, S J ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; THYMOCYTE ANTIBODY;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; GRAFT SURVIVAL; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT PLANNING;

ACUTE DISEASE; ACYCLOVIR; ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CHILD; FEMALE; GRAFT REJECTION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MUROMONAB-CD3; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 0033562518     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199905150-00002     Document Type: Article

References (33)

1. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: Summary of Society of Hematology Workshop. Sem Diagn Pathol 1997; 14: 8.
2. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10: 136.
3. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723.
4. Birkeland SA. Steroid-free immunosuppression in renal transplantation. Lancet 1996; 348: 1105.
5. Birkeland SA. Steroid-free immunosuppression after kidney transplantation with ATG induction and cyclosporine and mycophenolate mofetil maintainance therapy. Transplantation 1998; 66: 1207.
6. Birkeland SA, Elbirk A, Rohr N, Jørgensen KA. Analyzis of the inflammatory leukocyte mobilization in 838 fine needle aspiration biopsies in non-rejecting (day 1-90) kidney grafts and 465 biopsies in grafts before, during and after acute cellular rejection. Transplant Cytol 1994; 2: 308.
7. Birkeland SA, Gahrn-Hansen B, Andersen HMK, Rohr N, Larsen K-E, Jøorgensen KA. CMV-prophylaxis in antibody treated renal transplanted patients. Transplantation Proc 1995; 27: 3473.
8. Birkeland SA, Hamilton-Dutoit S, Sandvej K, et al. EBV induced post transplant lymphoproliferative disorder (PTLD). Transplant Proc 1995; 27: 3467.
9. Hamilton-Dutoit SJ, Pallesen G: Detection of Epstein-Barr virus small RNAs (EBERs) in routine paraffin sections using non-isotopic RNA/RNA in situ hybridisation. Histopathology 1994; 25: 101.
10. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995; 60: 547.
11. Riddler SA, Breinig MC, McKnight LC. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972.
12. Savoie A, Perpête C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2515.
13. Rowe DT, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, Todo S, Green M. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35: 1612.
14. Marker SC, Ascher NL, Kalis JM, Simmons RL, Najarian JS, Balfour HH Jr. Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients. Surgery 1979; 85: 433.
15. Ho M, Jaffke R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719.
16. Horneff MW, Bein G, Fricke L, et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 1995; 60: 474.
17. Crompton CH, Cheung RK, Donjon C, et al. Epstein-Barr virus surveillance after renal transplantation. Transplantation 1994; 57: 1182.
18. Birkeland SA. Malignancies occurring de novo after transplantation. Curr Opin Organ Transplant 1998; 3: 82.
19. Armitage JM, Kormos RL, Stuart S, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. Scientific sessions discussion. J Heart Lung Transplant 1991; 10: 877.
20. Trigg ME, Finlay JL, Sondel PM. Prophylactic aciclovir in patients receiving bone marrow transplants. N Engl J Med 1985; 312: 1708.
21. Shapiro RS, McClain K, Frizzera, et al. Epstein-Barr-virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234.
22. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr-virus associated B cell lymphoproliferative disorders after bone marrow transplantation. Blood 1988; 72: 520.
23. Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV conversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc 1991; 23: 1473.
24. Davis CL, Harrison KL, McVicar JP, Forg PJ, Bronner MP, Marsh CL. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant 1995; 9: 53.
25. Yao QY, Ogan P, Rowe M, Rickinson AB. Epstein-Barr-virus treated B cells persist in the circulation of aciclovir-treated virus carriers. Int J Cancer 1989; 43: 61.
26. Kuo PC, Dafoe DC, Alfrey EJ, Sibley RK, Scandling JD. Post-transplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation 1995; 59: 135.
27. Darenkov IA, Marcarelli MA, Basadonna GP, et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997; 64: 848.
28. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of aciclovir, ganciclovir and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 216.
29. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994; 57: 568.
30. Fleiss JL. Statistical methods for rates and proportions, 2nd ed. New York: Wiley, 1981: 38.
31. Alfrey EJ, Friedman AL, Grossman RA, et al. A recent decrease in the time to development of monomorphous and polymorphous posttransplantlymphoproliferative disorder. Transplantation 1992; 54: 250.
32. Ciancio G, Siquijor AP, Burke GW, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 1997; 11: 243.
33. Morris RE. Transplantation. Beware: shifting paradigm ahead. Lancet 1996; 1 (suppl II): 26.